TransMedics Group, Inc. develops and commercializes technologies for organ transplantation. The company focuses on increasing organ utilization and improving patient outcomes through its Organ Care System (OCS™) platform, which preserves organs for transplantation in patients with end-stage heart, lung, and liver failure. The OCS is designed to optimize organ quality and validate organ viability, serving as a multi-organ platform that leverages proprietary technologies across various organs.
No recent RNS announcements for 1TMDX across 1TMDX, TMDX.
No recent RNS announcements for 1TMDX across 1TMDX, TMDX.